Wave Life Sciences Ltd.
WVE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for WVE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · WVE
Wave Life Sciences Ltd. is a biotechnology company focused on developing RNA-targeted therapeutics using its proprietary PRISM platform, with a lead pipeline in neurological and rare diseases.
Key risk: Clinical development uncertainty
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 6 clinical trials for Wave Life Sciences Ltd..
Wave Life Sciences Ltd. is a biotechnology company focused on developing RNA-targeted therapeutics using its proprietary PRISM platform, with a lead pipeline in neurological and rare diseases.
- Cash and equivalents of $368.0M as of 2026-06-30 [sec].
- Total revenue of $2.3M and net loss of $69.4M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $518.4M as of 2026-06-30 [sec].
- Company continues to incur significant expenses for clinical trials, R&D, and internal cGMP manufacturing [sec_mda · as of 2026-07-30].
- Future capital requirements depend on progress of clinical programs, number of candidates, and manufacturing costs [sec_mda · as of 2026-07-30].
What works
- Wave Life Sciences has a strong cash position of $368.0M as of 2026-06-30, providing runway for ongoing R&D and clinical activities [sec].
- The company is investing in its proprietary PRISM platform to innovate and optimize its RNA-targeted therapeutic pipeline [sec_mda · as of 2026-07-30].
What to weigh
- The company reported a net loss of $69.4M for the period ended 2026-06-30, reflecting high operating expenses with limited revenue [sec].
- Wave Life Sciences is unable to estimate future capital outlays due to uncertainties in clinical development and potential collaborations [sec_mda · as of 2026-07-30].
- Expenses are expected to continue varying significantly based on clinical trial progress, number of programs, and manufacturing costs [sec_mda · as of 2026-07-30].
From the filings
Quoted directly from source documents.
Company expects to continue incurring significant expenses for R&D and manufacturing
“We expect to continue to incur significant expenses in connection with our ongoing research and development activities and our internal cGMP manufacturing activities.”
SEC MD&A · July 30, 2026
Future capital requirements depend on multiple factors including clinical progress and number of candidates
“Our future capital requirements for our therapeutic programs will depend on many factors, including: • the progress, results and costs of conducting research and continued preclinical and clinical development for our therapeutic programs and future potential pipeline candidates; • the number and characteristics of product candidates and programs that we pursue; • the cost of manufacturing clinical supplies of our product candidates;”
SEC MD&A · July 30, 2026
Risks & what to watch (3)›
Key risks
- Clinical development uncertainty — Progress and costs of clinical trials are uncertain, impacting capital needs [sec_mda · as of 2026-07-30].
- Ongoing net losses — Company reported net loss of $69.4M for period ended 2026-06-30, with limited revenue [sec].
- Dependence on future financing — Unable to estimate future capital outlays; may need additional funding [sec_mda · as of 2026-07-30].
What to watch
- Progress and results of ongoing clinical trials for pipeline candidates [sec_mda · as of 2026-07-30].
- Updates on the PRISM platform innovation and optimization [sec_mda · as of 2026-07-30].
- Any new collaborations or partnerships that could affect capital requirements [sec_mda · as of 2026-07-30].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Wave Life Sciences Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Wave Life Sciences Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
22.9 months
D/E 0.23 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
No upcoming catalysts tracked
4 buys · 4 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
233
Total value held
$1.09B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 26,975,505 | $195.6M |
| blackrock, inc. | 14,117,412 | $102.4M |
| maverick capital ltd | 11,317,399 | $82.1M |
| driehaus capital management llc | 5,431,021 | $39.4M |
| federated hermes, inc. | 5,317,457 | $38.6M |
| fmr llc | 5,192,761 | $37.6M |
| 683 capital management, llc | 4,900,000 | $35.5M |
| primecap management co/ca/ | 4,832,952 | $35.0M |
| m28 capital management lp | 4,588,284 | $33.3M |
| state street corp | 3,674,033 | $26.6M |
Showing top 10 of 233 institutional holders of Wave Life Sciences Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 10.8%
- Days to cover
- 3.9
- Shares short
- 16,720,976
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
WVE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Wave Life Sciences Ltd.?
Wave Life Sciences Ltd. is a biotechnology company focused on developing RNA-targeted therapeutics using its proprietary PRISM platform, with a lead pipeline in neurological and rare diseases.
What is Wave Life Sciences Ltd.'s lead drug candidate?
Wave Life Sciences Ltd.'s most advanced tracked candidate is WVE-006 (Phase 1) for Alpha-1 Antitrypsin Deficiency (AATD); Alpha-1 Antitrypsin Deficiency.
Who is the CEO of Wave Life Sciences Ltd.?
Dr. Paul B. Bolno M.B.A., M.D. is the chief executive officer of Wave Life Sciences Ltd. (WVE).
Where is Wave Life Sciences Ltd. headquartered?
Wave Life Sciences Ltd. (WVE) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Wave Life Sciences Ltd. focus on?
Wave Life Sciences Ltd. develops therapies across Oncology, Rare Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.